Itzhak Perlman Headlines Great Neck Park District’s Summer Concert Series
4 days ago
United States George Church is a pioneering geneticist and molecular engineer whose work has significantly advanced genomics and synthetic biology, leading to numerous biotech innovations.
George Church acts as the co-founder and lead geneticist for Colossal Biosciences, a company focused on de-extinction, particularly the woolly mammoth revival project.
Professor Church co-founded more than 50 biotech companies, including Veritas Genetics, which aimed at full human genome sequencing and bringing the benefits of genomic data to millions globally.
Editas Medicine is one of the many companies co-founded by Professor Church, focusing on gene therapy.
Gen9bio, specializing in Synthetic DNA, was founded with George Church's innovations as its basis.
George M. Church, Ph.D. serves as a Venture Partner at Catalio Capital Management.
Alacris Pharmaceuticals, a company focused on cancer systems therapeutics, was co-founded by George Church.
Knome, a human genomics company aimed at sequencing human genomes and correlating information mined from DNA, was co-founded by George Church.
ReadCoor, a spatial biology company, was co-founded by George Church.
George Church co-founded Nebula Genomics, a personal genomics company that uses blockchain and digital currency to monetize DNA, offering whole-genome sequencing services.
Manifold Bio, a therapeutics firm founded by George Church, pioneers a protein barcoding technology for drug discovery, securing a $40 million Series A investment.
Digid8 is a DNA dating company, co-founded by George Church, which aims to use genetic information for matchmaking.
Rejuvenate Bio, co-founded by Church, is a company dedicated to gene therapy to treat and prevent age-related diseases.
George Church serves on the scientific advisory board of BGI Group and established the 'George Church Institute of Regenesis' in collaboration with them, focusing on advanced genetic technologies.
George Church joined HLTH.network (formerly Shivom) as a co-founder, a healthcare blockchain startup aiming to create the world's first global genomics data sharing and analytics marketplace.
LS9, Inc., a green chemistry company focused on engineering bacteria to convert sugar into biofuels, was co-founded by George Church.
Joule Unlimited, a company focused on solar fuels by engineering photosynthetic bacteria, was co-founded by George Church.
In 2025, George Church joined Lila Sciences, an AI agent platform startup, as Chief Scientist.
George McDonald Church, born on August 28, 1954, on MacDill Air Force Base in Tampa, Florida, developed an early interest in mathematics, mineralogy, and entomology, alongside a fascination with computers. After attending Phillips Academy, he pursued a Bachelor of Science in zoology and chemistry at Duke University in two years. His initial research at Duke, focusing on X-ray crystallography, combined his interests in computers and biology, leading to his first peer-reviewed publication in 1977. Church then continued his graduate studies at Harvard University under Walter Gilbert, earning a Ph.D. in biochemistry and molecular biology in 1984. During his doctoral work, he contributed to understanding introns’ regulatory function in mitochondrial genomes and developed a method for direct genomic sequencing, which bypassed the need for bacterial cloning.
After a brief period at Biogen and a postdoctoral fellowship at the University of California, San Francisco, Church joined Harvard Medical School as an assistant professor in 1986. Throughout his career, he has been credited with numerous innovations that have shaped modern biotechnology. In 1984, he co-developed the first direct genomic sequencing method and was instrumental in initiating the Human Genome Project. He also introduced molecular multiplexing and barcode tags and co-invented nanopore sequencing in 1995. In 2005, he launched the Personal Genome Project to make human genomic and trait data publicly accessible, fostering a new era of personal genomics. Church’s laboratory has been a hub for translational research, leading to the co-founding of over 50 biotech companies. His contributions extend to synthetic biology, where he co-developed Multiplex Automated Genome Engineering (MAGE) and optimized CRISPR/Cas9 for genome editing, and has explored genome-scale changes for industrial and therapeutic applications.
His research spans diverse areas including developmental biology, neurobiology, medical genetics, aging, and space biology. Notably, Church is recognized for his work on gene therapy for age-related diseases, including co-founding Rejuvenate Bio. A significant and recent venture is Colossal Biosciences, co-founded in 2021, which aims at de-extinction, including the woolly mammoth revival project using genetic engineering. Through his extensive academic roles, including Robert Winthrop Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT, and his entrepreneurial endeavors, Church continues to drive innovation at the intersection of genetics, engineering, and medicine.
Curious about our offerings or have inquiries? We're eager to assist!
Just complete the form, and we'll respond promptly.
